Certara Q3 Earnings Call Highlights
Certara reported Q3 bookings up 4% to $92.5M, with a net loss of $3.6M. The company is accelerating cloud conversions and AI integration, expecting growth impacts in 2027. It narrowed FY2026 revenue growth outlook to 2-3% and updated adjusted earnings outlook to $0.31-$0.34 per share. Certara has $214.9M in cash and $100M available under its revolving credit facility.
How this was made

The 30-second read
Why it matters
The earnings release narrows growth expectations and signals a near‑term revenue headwind from cloud migration, likely prompting a short‑term price decline.
Market read
First‑report earnings with revised guidance; relevant for biotech software investors.
What to watch
Cash position of $214.9M and ongoing credit facilities provide financial flexibility despite short‑term guidance weakness.
Background
Certara (NASDAQ:CERT) provides software and services for drug development, reporting Q3 results and updated 2026 guidance.
Ticker impact
Q3 earnings report shows narrowed 2026 revenue growth outlook to 2%-3% and adjusted earnings guidance of $0.31-$0.34 per share.
likely pressure as the market prices in weaker revenue growth and earnings outlook
The company cut its full‑year revenue growth outlook and provided modest earnings guidance, which typically triggers a sell‑off in the short term.
Market effects
Software and services for drug development may see broader scrutiny as peers evaluate similar guidance trends.
Limited to U.S. biotech and pharma software niche; no broad regional effect.
Minor, confined to investors tracking quantitative modeling and regulatory software providers.
Counterpoint
The cloud conversion and AI initiatives could unlock higher-margin recurring revenue in 2027, offering a longer‑term upside.
Key entities
- ExecutiveResnick
CEO who discussed earnings and cloud conversion plans.
- ExecutiveFaiz Mohammed
Interim CFO who presented the financial details.




